Treatment of the Biceps With Concomitant Supraspinatus Tears

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-80
SponsorLa Tour Hospital

About this trial

The long head of the biceps (LHB) tendon is thought to be a common source of shoulder pain and dysfunction in patients with rotator cuff pathology. Tenotomy and tenodesis have been shown to produce favourable and comparable results in treating LHB lesions, but a controversy still exists regarding the treatment of choice. Some suggest that tenotomy should be reserved for older, low-demand patients, while tenodesis should be performed in younger patients and those who engage in heavy labor. Proponents of tenotomy suggest that this is a technically easy procedure that leads to easy rehabilitation and fast return to activity with a low complication and reoperation rate. However, those who support LHB tenodesis list good preservation of elbow flexion and supination strength, improvement of functional scores, elimination of pain, and avoidance of cosmetic deformity as benefits of the procedure. Alternatively, the LHB can be maintained in the joint without tenodesis or tenotomy. In fact, it has not been clearly shown that LHB tenodesis or tenotomy leads to improved outcomes compared to leaving the biceps tendon intact.

Eligibility criteria

Qualifiers

Patient voluntarily consents to participate in the study and has the mental and physical ability to participate in the study, fill out subjective questionnaires, return for follow-up visits, and comply with prescribed post-operative physical therapy.

Full thickness tear of the supraspinatus tendon

Intact subscapularis tendon

Primary rotator cuff repair

Disqualifiers

Previous full thickness biceps tear

Infection and neuropathic joints

Known or suspected non-compliance, drug or alcohol abuse

Patients incapable of judgement or under tutelage

Trial design

Treatments tested in this trial

  • LHB Tenotomy
  • LHB Tenodesis

Treatment groups

180 Participants
are divided into 3 treatment groups

Sponsors and collaborators